Merrill Lynch analyst Jason Gerberry maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) on Thursday, setting a price target of $167, which is approximately 49.67% above the present share price of $111.58.
Gerberry expects Jazz Pharmaceuticals to post earnings per share (EPS) of -$2.82 for the second quarter of 2020.
The current consensus among 10 TipRanks analysts is for a Strong Buy rating of shares in Jazz Pharmaceuticals, with an average price target of $155.7.
The analysts price targets range from a high of $193 to a low of $109.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $534.73 million and a net profit of $148.72 million. The company's market cap is $6.12 billion.
According to TipRanks.com, Merrill Lynch analyst Jason Gerberry is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.0% and a 38.64% success rate.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.